tert-butyl 4-(4-(pyridin-3-yl)phenyl)piperazine-1-carboxylate | 374930-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(4-(pyridin-3-yl)phenyl)piperazine-1-carboxylate
• 英文别名: 4-(4-Pyridin-3-yl-phenyl)piperazine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(4-pyridin-3-ylphenyl)piperazine-1-carboxylate
• CAS: 374930-84-4
• 化学式: C₂₀H₂₅N₃O₂
• 分子量: 339.437
• InChiKey: CQGJRVIBZKHVLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-(pyridin-3-yl)phenyl)piperazine-1-carboxylate 在 水 作用下， 以 四氢呋喃 、 盐酸 为溶剂， 反应 1.0h， 以affording 50 mg (100%) of the title compound as a yellow powder的产率得到1-(4-(pyridin-3-yl)phenyl)piperazine
  参考文献：
  名称：

  Metalloproteinase inhibitors

  摘要：

  本发明提供了一种金属蛋白酶抑制剂化合物，其包含具有式（I）的金属结合基团，用于治疗由一种或多种金属蛋白酶酶介导的疾病或病况，其中X选自NR1、O、S；B为C或CH，Y1和Y2独立地选自O、S；R1选自H、烷基、卤代烷基。

  公开号：

  US20040147573A1
• 作为产物：
  描述：

  3-吡啶硼酸 、 4-(4-碘苯基)四氢-1(2H)-吡嗪羧酸叔丁酯 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 1.0h， 以45%的产率得到tert-butyl 4-(4-(pyridin-3-yl)phenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Further delineation of hydrophobic binding sites in dopamine D2/D3 receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol

  摘要：

  Here we report a structure-activity relationship (SAR) study of analogues of 5/7-{[2-(4-aryl-piperazin-1-yl)- ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol. Our SAR is focused on introduction of various substitutions in the piperazine ring of the hybrid template. The goal behind this study is to delineate the nature of the binding pocket for N-aryl substitution in the piperazine ring by observing the effect of various hydrophobic and other heteroaromatic substitutions on binding affinity (K-i), as measured with tritiated spiperone and HEK-293 cells expressing either D-2 or D-3 receptors. Functional activity of selected compounds was assessed with the GTP gamma S binding assay. Compound 8d was the most selective for the D-3 receptor in the spiperone binding assay. An interesting similarity in binding affinity was observed between isoquinoline derivative D-301 and the 2-substituted pyridine derivative 8d, suggesting the importance of relative spatial relationships between the N-atom of the ligand and the molecular determinants of the binding pocket in D-2/D-3 receptors. Functional activity assays demonstrated high potency and selectivity of (+)-8a and (-)-28b (D-2/D-3 (ratio of EC50): 105 and 202, respectively) for the D-3 receptor and both compounds were more selective compared to the reference drug ropinirole (D-2/D-3 (ratio of EC50): 29.5). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.025

文献信息

• GUANIDINE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20130143860A1

  公开（公告）日：2013-06-06

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

  [问题]本发明提供一种化合物，用作药物组合物的活性成分，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物。 [解决方法]本发明人对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的化合物或其盐表现出优异的VAP-1抑制活性，可用于预防和/或治疗与VAP-1相关的疾病，特别是糖尿病肾病或糖尿病黄斑水肿，从而完成了本发明。此外，本发明涉及一种药物组合物，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物，其包括本发明的化合物或其盐和赋形剂。
• Metalloproteinase inhibitors
  申请人：——

  公开号：US20040127528A1

  公开（公告）日：2004-07-01

  Compounds of the formula (I) wherein z is SO 2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.

  式(I)的化合物，其中z为SO2或SO，可用作金属蛋白酶抑制剂，特别是MMP12的抑制剂。
• Metalloproteinase Inhibitors
  申请人：Eriksson Anders

  公开号：US20080306065A1

  公开（公告）日：2008-12-11

  Compounds of the formula (I) wherein z is SO 2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.

  公式为（I）的化合物，其中z为SO2或SO，可用作金属蛋白酶抑制剂，特别是作为MMP12的抑制剂。
• Hydantoin derivatives as MMP inhibitors
  申请人：AstraZeneca AB

  公开号：EP1676846A2

  公开（公告）日：2006-07-05

  Compounds of the formula I wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.

  式 I 的化合物 其中 z 为 SO2 或 SO，可用作金属蛋白酶抑制剂，尤其是 MMP12 的抑制剂。
• 10.1002/chem.202401552
  作者：Surgenor, Richard R.、Lee, Hyelee

  DOI：10.1002/chem.202401552

  日期：——

  The (hetero)biaryls are fundamental to drug discovery and rapid, general access to these motifs is essential for medicinal chemistry. Herein, a nickel catalyzed reductive cross-electrophile coupling between heteroaryl iodides and bromides is described. We demonstrated that the reaction is chemoselective, scalable, and amenable to library fashion with an array of scaffolds (45 examples).

  （杂）联芳基是药物发现的基础，快速、普遍地获取这些基序对于药物化学至关重要。本文描述了杂芳基碘化物和溴化物之间的镍催化还原交叉亲电子偶联。我们证明了该反应具有化学选择性、可扩展，并且适合具有一系列支架的库时尚（45 个示例）。